Relapse of Palmoplantar Pustulosis Following COVID-19 Vaccination

Katsuie, Shiho; Nakamura, Kenzo; Ogawa, Emiko; Arakura, Fuyuko; Okuyama, Ryuhei

doi:10.7759/cureus.28604

Cited by 2 publications

(2 citation statements)

References 14 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 164 non‐injection‐site reactions in 161 patients have been reported in previous case reports and series 7–88 . Patients with systemic lupus erythematosus (SLE) and lupus erythematosus profundus (LEP) showed exacerbation of lupus eruptions after 2 weeks, and other AEs developed several months later.…”

Section: Resultsmentioning

confidence: 99%

Cutaneous adverse events following COVID‐19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies

Baba,

Yamada,

Kanekura

2024

The Journal of Dermatology

View full text Add to dashboard Cite

In Japan, cutaneous adverse events (AEs) following the coronavirus disease 2019 (COVID‐19) vaccination have been frequently described; however, a larger case series and literature review are lacking. There is an urgent need for an extensive investigation of new cases and previous reports to provide a thorough body of information about post‐COVID‐19 immunization cutaneous AEs. We aimed to analyze patients with cutaneous AEs after COVID‐19 vaccination in our hospital and review previous studies of cutaneous AEs. We analyzed post‐COVID‐19 vaccination cutaneous AEs in our department, the Japanese Registry, and previous literature. We enrolled 30 patients with cutaneous post‐vaccination AEs in our department over 2 years (April 1, 2021, to March 31, 2023). We also confirmed cases registered in the Ministry of Health, Labor, and Welfare COVID‐19 vaccine side effect reporting system (February 17, 2021–March 12, 2023). A total of 587 records were retrieved and 93 articles were included for data extraction. A total of 28 non‐injection‐site cutaneous AEs and two injection‐site AEs were identified. Six (20.0%) patients developed new‐onset erythematous eruptions, and five (16.7%) patients developed urticaria. Pruritic eruption, eczema, shingles, and sweating symptoms have also been reported. In previous studies on non‐injection‐site cutaneous AEs, individuals who received the BNT162b2 vaccine were older than those who received mRNA‐1273 (P < 0.01). Cutaneous AEs were mostly nonsignificant and self‐limiting reactions; however, rare, severe, or life‐threatening AEs were also reported. Physicians should be aware of the various possible cutaneous AEs associated with the COVID‐19 vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Cutaneous adverse events following COVID‐19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies

Baba,

Yamada,

Kanekura

2024

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Amongst the patients, sex was almost equally distributed (Male:4 Female:5) and the age range was 38 to 80 years old. Most of the eruptions occurred the fourth or fifth day after the vaccination, with two cases occurring from the same article referring a postvaccination period of one month [ 35 ]. The responsible vaccine types were the Pfizer ( n = 5) and Moderna ( n = 3) vaccines.…”

Section: Resultsmentioning

confidence: 99%

Pustular Eruption following COVID-19 Vaccination: A Narrative Case-Based Review

Karampinis,

Gravani,

Gidarokosta

et al. 2023

Vaccines

View full text Add to dashboard Cite

From the beginning of public vaccinations until the relaxation of COVID-19 measures, many case reports, case series and case–control studies have been published indicating cutaneous side effects of COVID-19 vaccination. Post-vaccination pustular eruption was reported as well, with a challenging differential diagnosis between pustular psoriasis, AGEP (acute generalized exanthematous pustulosis) and neutrophil pustular eruptions. We report a case of 56-year-old woman presented with acute generalized pustular flare up culminated 5 days after the second dose of BNT162b2(Pfizer) vaccination. She was diagnosed with pustular psoriasis flare and due to the regulating role of IL-1 in pustular psoriasis and in the cytokine storm observed in cases of COVID-19 postvaccination inflammation; we decided to treat the patient with an IL-1 antagonist, subcutaneous anakinra (100 mg daily) along with acitretin. One week later, after anakinra withdrawal, she presented a pustular psoriasis flare and a 7-day anakinra re-administration led to a satisfactory improvement in the skin lesions. We also reviewed the medical literature and found 28 case reports with pustular eruption after the COVID-19 vaccination. We compared the patients reported, regarding sex, age, number of doses, post-vaccination period and vaccine brand, and compared those results with our patient. Finally, as indicated by our case and other cases with similarly treated pustular eruptions. targeted therapy to this cytokine imbalance such as anakinra (IL-1) antagonist can improve the clinical course of the patient.

show abstract

Relapse of Palmoplantar Pustulosis Following COVID-19 Vaccination

Cited by 2 publications

References 14 publications

Cutaneous adverse events following COVID‐19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies

Cutaneous adverse events following COVID‐19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies

Pustular Eruption following COVID-19 Vaccination: A Narrative Case-Based Review

Contact Info

Product

Resources

About